Legend Biotech has reported five-year follow-up data showing that half of patients with relapsed or refractory multiple myeloma in CARTITUDE-2 Cohort A remained alive, progression-free and free from further anti-myeloma treatment after receiving a single infusion of CARVYKTI. Median progression-free survival reached 60.5 months, while the five-year overall survival rate was 69.2% and median overall survival had not yet been reached. The results provide some of the longest follow-up available for CARVYKTI when used after only one to three prior lines of therapy and strengthen the evidence that earlier CAR T-cell treatment can produce unusually durable remissions in selected patients.
The findings should nevertheless be interpreted carefully because CARTITUDE-2 Cohort A included only 20 patients and was not designed as a randomized comparison against another therapy. Legend Biotech has described the durability as supporting CARVYKTI’s potential to produce outcomes approaching functional cure in some patients, but the current dataset does not establish that multiple myeloma has been permanently eradicated. The more defensible conclusion is that a meaningful proportion of this small cohort remained treatment-free without disease progression for at least five years after a single CARVYKTI infusion.
Five-year CARTITUDE-2 results extend CARVYKTI remission well beyond the initial treatment period
CARTITUDE-2 Cohort A evaluated ciltacabtagene autoleucel, marketed as CARVYKTI, in adults with relapsed or refractory multiple myeloma who had previously received one to three lines of therapy and were refractory to lenalidomide. Patients received a single infusion of the B-cell maturation antigen-directed CAR T-cell therapy and were then followed for long-term disease progression, survival and safety.
At a median follow-up of 60.7 months, 10 of the 20 participants remained alive and progression-free without receiving maintenance therapy or any additional anti-myeloma treatment. Median progression-free survival was 60.5 months, indicating that disease control in the overall cohort lasted approximately five years before half the patients had progressed or died.
Overall survival remained encouraging as well. Approximately 69.2% of patients were alive at five years, and median overall survival had not been reached at the time of the analysis. These findings reinforce earlier CARVYKTI studies suggesting that treatment durability may improve when the therapy is used sooner in the multiple myeloma treatment sequence rather than after patients have exhausted numerous prior options.
The study population is important to that interpretation. CAR T-cell therapy was initially developed largely for heavily pretreated patients with few remaining options, but CARTITUDE-2 examined patients much earlier in their treatment course. Patients receiving fewer prior therapies may enter CAR T treatment with fitter immune systems, lower disease burden or other biological advantages that could contribute to longer remissions.
Those possibilities remain hypotheses rather than conclusions from this single cohort. The study does not show that earlier use alone caused the five-year benefit, and larger randomized trials are required to separate the effect of timing from differences in patient selection.
Earlier CARVYKTI use is becoming increasingly important to the multiple myeloma treatment strategy
CARVYKTI is already approved in the United States for adults with relapsed or refractory multiple myeloma after at least one prior line of therapy when patients are lenalidomide-refractory. The expansion into earlier treatment was supported by the randomized CARTITUDE-4 program and significantly increased the number of patients potentially eligible for the therapy.
The latest long-term data strengthen the argument that CARVYKTI may be particularly valuable before patients cycle through multiple additional therapies. Multiple myeloma has historically been managed through successive lines of treatment, with patients often moving from combination regimens to subsequent targeted therapies as the disease returns.
A therapy capable of producing several years without treatment could substantially alter that pattern for responders. Long treatment-free periods may reduce cumulative toxicity, infusion visits and the physical and psychological burden associated with moving repeatedly between therapies.
However, CARVYKTI also carries significant risks and logistical requirements. CAR T-cell treatment involves collecting a patient’s own T cells, genetically engineering them to recognize B-cell maturation antigen and reinfusing them after lymphodepleting chemotherapy. The process requires specialized treatment centers and monitoring for potentially serious toxicities.
Across larger CARVYKTI studies, neurological toxicities, cytokine release syndrome, prolonged cytopenias and serious infections have been reported. Parkinsonism-like neurological events have occurred in a small proportion of patients, while delayed blood-count recovery and infections remain clinically relevant considerations.
In CARTITUDE-2 Cohort A, no new CAR T-cell-related neurological toxicity was reported during the extended follow-up period. One additional hematologic malignancy, acute myeloid leukemia, was reported since the previous analysis, while two additional deaths resulted from progressive disease and a new cancer.
The long-term benefit therefore needs to be evaluated against the acute and delayed risks associated with a one-time cellular therapy. The current data support durable efficacy, but they do not remove the need for careful patient selection and continued long-term safety surveillance.
CARVYKTI commercial growth gives Legend Biotech a strong platform behind the long-term clinical story
The five-year results arrive while CARVYKTI continues to become increasingly important to Legend Biotech’s financial profile. Second-quarter net trade sales reached approximately $657 million, representing 50% growth from the same period a year earlier. United States sales increased 32%, while sales outside the United States rose 128%, reflecting expanding availability across international markets.
CARVYKTI was available at 348 treatment sites across 19 markets by the end of the second quarter. Legend Biotech develops and commercializes the therapy with Johnson & Johnson under a global collaboration, with Legend Biotech recognizing its share of revenue and costs under the partnership.
Higher CARVYKTI sales have materially improved Legend Biotech’s financial performance. Collaboration revenue rose to $326.1 million during the second quarter from $219.7 million a year earlier, while the company recorded operating income of $57.7 million compared with a $21.9 million operating loss in the prior-year period. Net income reached $33.2 million compared with a $125.4 million loss a year earlier.
Legend Biotech also ended June with approximately $965 million in cash, cash equivalents and time deposits after raising roughly $212 million through a public offering. Management has said it expects the business to reach company-wide adjusted profitability during 2026, supported largely by continued CARVYKTI expansion.
That commercial momentum increases the importance of long-term remission data. CAR T-cell therapies carry high upfront costs and complex manufacturing requirements, making durability central to their broader value proposition. Evidence that a single treatment can keep some patients free from progression and additional therapy for five years strengthens the argument that the upfront intervention may replace years of sequential treatment in selected patients.
Legend Biotech investors now have to balance strong CARVYKTI growth with high expectations for long-term expansion
Legend Biotech shares entered the September 25 session at $19.06 after gaining 3.3% in the previous trading session. The stock remains substantially below its 52-week high of $37.50 despite continued CARVYKTI growth, reflecting investor concerns around competition, manufacturing scalability, leadership changes and the long-term valuation of the company beyond its lead product.
Analyst sentiment remains broadly favorable but has become more mixed than earlier in the year. S&P Global data compiled by StockAnalysis show 14 analysts with an average Buy rating and a mean price target of $48.48, while MarketBeat reports a Hold consensus across a somewhat different analyst sample. The divergence illustrates that the market remains optimistic about CARVYKTI’s commercial potential but less uniform in its assessment of Legend Biotech’s broader valuation.
The five-year CARTITUDE-2 results could help reinforce the clinical side of the investment argument by showing that CARVYKTI’s value may extend far beyond near-term response rates. The larger commercial question is whether that durability can be reproduced consistently as treatment moves earlier, expands internationally and reaches broader patient populations.
The dataset should not be interpreted as proof of cure, particularly given the small 20-patient cohort. It does, however, demonstrate that prolonged treatment-free disease control is possible for some patients after a single CARVYKTI infusion. In a disease traditionally managed through repeated lines of therapy, that five-year durability is clinically meaningful and increasingly relevant to how CARVYKTI may be positioned earlier in multiple myeloma treatment.
